Literature DB >> 2805409

Occurrence of platelet-activating factor (PAF) and an endogenous inhibitor of platelet aggregation in diffuse cutaneous mastocytosis.

J L Macpherson1, A Kemp, M Rogers, A I Mallet, R F Toia, B Spur, J W Earl, C N Chesterman, S A Krilis.   

Abstract

We have identified PAF in the blister fluid from a patient with bullous mastocytosis, a rare form of mast-cell disease. We have found a novel endogenous inhibitor of platelet aggregation which obscured the presence of the PAF in unprocessed blister fluid and in ethanol or lipid extracts. The PAF was characterized by the demonstration of chromatographic, mass spectral and biological properties identical to those of authentic PAF. Thus this is the first demonstration of PAF in biological fluid from a patient with mastocytosis. High levels of immunoreactive prostaglandin D2 (PGD2) and histamine were also present in the blister fluid. The interaction between PAF and the inhibitor of platelet aggregation in patients with systemic mastocytosis may provide an explanation for some of the manifestations of the disease, in particular the episodic hypotension, cutaneous flushing and pallor.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2805409      PMCID: PMC1542063     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  21 in total

1.  Increased production of prostaglandin D2 in patients with systemic mastocytosis.

Authors:  L J Roberts; B J Sweetman; R A Lewis; K F Austen; J A Oates
Journal:  N Engl J Med       Date:  1980-12-11       Impact factor: 91.245

2.  Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites.

Authors:  J J Keyzer; J G de Monchy; J J van Doormaal; P C van Voorst Vader
Journal:  N Engl J Med       Date:  1983-12-29       Impact factor: 91.245

3.  Rapid assay for amino acids in serum or urine by pre-column derivatization and reversed-phase liquid chromatography.

Authors:  D C Turnell; J D Cooper
Journal:  Clin Chem       Date:  1982-03       Impact factor: 8.327

4.  Bullous mastocytosis: diffuse cutaneous mastocytosis with extensive blisters mimicking scalded skin syndrome or erythema multiforme.

Authors:  L E Golitz; W L Weston; A T Lane
Journal:  Pediatr Dermatol       Date:  1984-04       Impact factor: 1.588

5.  Accumulation of inflammatory cells in response to intracutaneous platelet activating factor (Paf-acether) in man.

Authors:  C B Archer; C P Page; J Morley; D M MacDonald
Journal:  Br J Dermatol       Date:  1985-03       Impact factor: 9.302

6.  High performance liquid chromatography of platelet-activating factors.

Authors:  E M Jackson; G E Mott; C Hoppens; L M McManus; S T Weintraub; J C Ludwig; R N Pinckard
Journal:  J Lipid Res       Date:  1984-07       Impact factor: 5.922

7.  Cromoglycate (DSCG) inhibits responses to platelet-activating factor (PAF-acether) in man: an alternative mode of action for DSCG in asthma?

Authors:  G S Basran; C P Page; W Paul; J Morley
Journal:  Eur J Pharmacol       Date:  1982-12-17       Impact factor: 4.432

8.  Release, purification, and characterization of platelet-activating factor (PAF).

Authors:  V Tencé; J Polonsky; J P Le Couedic; M J Benveniste
Journal:  Biochimie       Date:  1980       Impact factor: 4.079

9.  Release of platelet-activating factor and histamine. I. Effect of immune complexes, complement and neutrophils on human and rabbit mastocytes and basophils.

Authors:  G Camussi; J M Mencia-Huerta; J Benveniste
Journal:  Immunology       Date:  1977-10       Impact factor: 7.397

10.  Effect of platelet-activating factor (PAF) on human platelets.

Authors:  C M Chesney; D D Pifer; L W Byers; E E Muirhead
Journal:  Blood       Date:  1982-03       Impact factor: 22.113

View more
  5 in total

Review 1.  Diagnosis and treatment of cutaneous mastocytosis in children: practical recommendations.

Authors:  Mariana Castells; Dean D Metcalfe; Luis Escribano
Journal:  Am J Clin Dermatol       Date:  2011-08-01       Impact factor: 7.403

Review 2.  Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Authors:  M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

3.  Inactivation of platelet-activating factor by a putative acetylhydrolase from the gastrointestinal nematode parasite Nippostrongylus brasiliensis.

Authors:  C C Blackburn; M E Selkirk
Journal:  Immunology       Date:  1992-01       Impact factor: 7.397

Review 4.  Forty Years Since the Structural Elucidation of Platelet-Activating Factor (PAF): Historical, Current, and Future Research Perspectives.

Authors:  Ronan Lordan; Alexandros Tsoupras; Ioannis Zabetakis; Constantinos A Demopoulos
Journal:  Molecules       Date:  2019-12-03       Impact factor: 4.411

Review 5.  Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.

Authors:  Magdalena Lange; Karin Hartmann; Melody C Carter; Frank Siebenhaar; Ivan Alvarez-Twose; Inés Torrado; Knut Brockow; Joanna Renke; Ninela Irga-Jaworska; Katarzyna Plata-Nazar; Hanna Ługowska-Umer; Justyna Czarny; Anna Belloni Fortina; Francesca Caroppo; Roman J Nowicki; Bogusław Nedoszytko; Marek Niedoszytko; Peter Valent
Journal:  Int J Mol Sci       Date:  2021-03-04       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.